A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer

BACKGROUND: Triple-negative breast cancer (TNBC) remains an aggressive breast cancer subtype with limited treatment options. ENMD-2076 is a small-molecule inhibitor of Aurora and angiogenic kinases with proapoptotic and antiproliferative activity in preclinical models of TNBC. METHODS: This dual-ins...

Descripción completa

Detalles Bibliográficos
Autores principales: Diamond, Jennifer R., Eckhardt, S. G., Pitts, Todd M., van Bokhoven, Adrie, Aisner, Dara, Gustafson, Daniel L., Capasso, Anna, Sams, Sharon, Kabos, Peter, Zolman, Kathryn, Colvin, Tiffany, Elias, Anthony D., Storniolo, Anna M., Schneider, Bryan P., Gao, Dexiang, Tentler, John J., Borges, Virginia F., Miller, Kathy D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090978/
https://www.ncbi.nlm.nih.gov/pubmed/30071865
http://dx.doi.org/10.1186/s13058-018-1014-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090978/
https://www.ncbi.nlm.nih.gov/pubmed/30071865
http://dx.doi.org/10.1186/s13058-018-1014-y

Ejemplares similares